Ceftobiprole Medocaril Free Acid

Summary

Ceftobiprole Medocaril Free Acid (CHEMBL1652606) is an approved small molecule (ATC J01DI01); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DI01
• Indications: 1 condition
• Clinical trials: 12
• Chemistry: 690.7 Da · C26H26N8O11S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1652606
Name	Ceftobiprole Medocaril Free Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	135456161
ATC	J01DI01
Molecular formula	C26H26N8O11S2
Molecular weight	690.7
InChIKey	HFTSMHTWUFCYMJ-FDNJTQOMSA-N

SMILES: CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N/O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O

IUPAC name: (6R,7R)-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Also known as: Ceftobiprol medocarilo, Ceftobiprole medocaril, Ceftobiprole medocaril free acid, CEFTOBIPROLE MEDOCARIL FREE ACID

Parent form; salt/anhydrous children: CHEMBL4297101

Patent coverage: 44 distinct patent families (101 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	-1	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	8
PHASE2	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00210899	PHASE3	COMPLETED	Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
NCT00228982	PHASE3	COMPLETED	Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
NCT00326287	PHASE3	COMPLETED	Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT03137173	PHASE3	COMPLETED	Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
NCT03138733	PHASE3	COMPLETED	Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
NCT03439124	PHASE3	COMPLETED	Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
NCT05856227	PHASE3	COMPLETED	Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
NCT00505258	PHASE2	WITHDRAWN	Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
NCT03317093	PHASE2	COMPLETED	Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device
NCT02527681	PHASE1	TERMINATED	Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
NCT04170309	Not specified	COMPLETED	Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).